Nelson Vergel (PowerUSA.org) moderates a webcast with two leading HIV Cure research activists: Richard Jeffreys and Robert Reinhard. They update us on progress made after a cure was possible for Timothy Brown, the only person cured of HIV in 2007. ABOUT THE SPEAKERS: Richard Jefferys began working in the HIV/AIDS field in 1993 at the …
HIV Cure Update 2017: Interview with Leading Research Advocates Read More »
We are constantly reading headlines about the latest HIV cure. After years of being exposed to these inflamed news reports, we may get desensitized to the fact that there is actually progress being made in that field. Ever since Timothy Brown was proven to be cured, the search for a cure for HIV that is …
How Researchers Are Now Trying to Cure More HIV+ People Read More »
This past March, the 20th Conference on Retroviruses and Opportunistic Infections (CROI) brought an unprecedented flurry of mainstream interest in potential HIV cure strategies. TheBodyPRO.com’s Nelson Vergel sat down with leading HIV cure research activist Richard Jefferys for an update on current important aspects, and controversies, in HIV cure research. Jefferys, who coordinates the Basic Science Vaccines …
“Both the surviving patients had been receiving prolonged antiretroviral therapy and received stem cell transplants with a reduced-intensity conditioning regimen of chemotherapy designed to eradicate the cancer and eliminate the existing bone marrow. In the case of the two patients under investigation, the conditioning regimen did not include radiotherapy and it did not eliminate the …
Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen Read More »
Argos Therapeutics Announces Plans for HIV Eradication Study “To create AGS-004, ribonucleic acid (RNA) is isolated from HIV particles obtained from patients, and dendritic cells are generated from a single leukapheresis procedure. Selected RNAs are then used to “program” the dendritic cells with the patient-specific payload to trigger an immune response against the patient’s HIV …
I highly encourage everyone to join our important attempt to accelerate the cure of HIV. Research Match also helps connect patients with other diseases with private investigators. Please forward to your friends and families. Anyone can participate. Thank you in advance for supporting this platform! Contact: Kathy Edson (615) 343-2571/ kathleen.edson@vanderbilt.edu ResearchMatch Connects HIV Study Volunteers with Researchers Nashville, TN – June 1, 2013 — ResearchMatch (RM), the country’s first nationwide, non-profit research volunteer recruitment platform for all …
ResearchMatch Connects HIV Study Volunteers with Researchers Read More »
SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH ZFP THERAPEUTIC®, SB-728-T Unprecedented Immune Reconstitution Drives HIV Viral Reservoir DepletionEncouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 Trials Richmond, California, May 15, 2013 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new …
NATAP http://natap.org/_______________________________________________ “Functional Cure” of HIV Claimed for Baby Treated 30 Hours After Birth 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta Mark Mascolini An HIV-infected US infant treated from 30 hour after birth had no detectable viral load, no detectable HIV DNA in blood cells, and no HIV-specific antibodies at 26 months …
“Functional Cure” of HIV Claimed for Baby Treated 30 Hours After Birth Read More »
Reality Check: Is the End of AIDS in Sight? Dr Francois Dabis from the Bordeaux School of Public Health at the University of Bordeaux (Segalen, France) gave an excellent talk today at CROI-2013 that is easily understood by any lay person who wants to know how far we have come in HIV and the challenges ahead …
http://www.thebodypro.com/content/70316/innovative-hiv-gene-therapy-study-soon-to-start-en.html
Although the development of cell-based and gene transfer therapies has been slow, progress in a number of areas is evident. Advances in the fields of gene-targeting strategies, T-cell-based approaches, and HSCs have been encouraging, and a series of ongoing and planned trials to establish proof of concept for strategies that could lead to successful cell …
